Fidson Healthcare Plc, Nigeria’s foremost pharmaceutical company, today announced a strategic partnership with Liddie BE Ltd, a renowned Clinical Research Organization, to conduct a Bioequivalence (BE) study on their chewable formulation of Albendazole tablets.
Albendazole is an FDA approved medication for the treatment of a variety of parasitic worm infections prevalent in Nigeria and many parts of the world. The BE study will be conducted under stringent regulatory guidelines that meet international standards and will compare the pharmacokinetics of the novel Albendazole formulation with the standard reference.
This partnership is groundbreaking in the advancement of clinical research, being the first Bioequivalence study to be conducted in Nigeria. Speaking at the joint press conference to announce this collaboration, Dr. Fidelis Ayebae, the CEO of Fidson stated, “we are excited again to be at the forefront of innovation and leadership in the healthcare industry in Nigeria with this landmark effort. This study is a critical step towards the WHO Prequalification of our brand of chewable Albendazole tablets. This collaboration being the first BE study in Nigeria and one of the first in Africa is a testament to the success of indigenous efforts and vision which we are very proud to lead.”
Prof. Lara Orafidiya, Managing Director of Liddie BE Ltd, added, “we are happy to partner with Fidson on this critical study. Our expertise in clinical research will ensure that this product meets the required international standards for safety and efficacy. We are committed to contributing to the healthcare landscape in Nigeria through world class clinical trials and research”
The study results are expected to provide key data to support the WHO-PQ programme of the product. This initiative attests to both companies’ commitment to advancing healthcare access and improving clinical outcomes in Nigeria and across the continent.
L-R: Mr. Biola Adebayo, Deputy Managing Director, Fidson Healthcare Plc.; Mr. Bolakale Ayinde, Director, Clinical Research & Drug Development Liddie BE Ltd; Mrs. Osayuwa Oyebola Wuraola, Chief Nurse, Liddie BE Ltd; Dr. Fidelis Ayebae, Founder/Managing Director, Fidson Healthcare Plc; Mr. Wale Ogunsola, Chief Operating Officer, Liddie BE Ltd; Mr. Olugbenga Olayeye Strategy and Marketing Director, Fidson Healthcare Plc. At the announcement of the Bio-Equivalent study for Albendazole in Lagos Nigeria.
